Cargando…
Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS)
Background: Immunosuppression by biologic response modifiers (BRM) is a crucial component for successful organ transplantation. In addition to their variable effectiveness in the prevention of organ rejection, these medications have safety concerns that complicate therapeutic outcomes in organ trans...
Autor principal: | Ali, A. K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Avicenna Organ Transplantation Institute
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089314/ https://www.ncbi.nlm.nih.gov/pubmed/25013655 |
Ejemplares similares
-
Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023) -
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022) -
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022) -
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022) -
Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2019)